Immuneering
Price & Volume
Stats
See moreOpen | $5.08 |
Previous Close | $4.99 |
Day Range | $4.88-$5.16 |
52W Range | $2.90-$10.08 |
Market Cap | $325.4M |
Shares Short | 14M |
Financials
See moreRevenue (12 Mos) | $455 |
Revenue Growth (YoY) | -99.8% |
Gross Profit (12 Mos) | $158,830 |
Diluted EPS | -$1.06 |
News
See moreYahoo Finance • 17 days ago
Immuneering Appoints Andrew Gengos as Chief Financial Officer
Yahoo Finance • 21 days ago
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Yahoo Finance • last month
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Yahoo Finance • 3 months ago
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings
About
CEO | Dr. Benjamin J. Zeskind M.B.A., Ph.D. |
Address | 245 Main Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 55 |